Diabetes Treatment Success Rates less than 50%, Drugs Are in Urgent Need of Innovation to Deal with the Challenges of Diabetes


RDPAC released the 2017  report of Meet the  Challenges of Diabetes with Drug Innovation  


[November  9, 2017, Shanghai] During the 26th “World Diabetes Day” approaching, RDPAC  released 2017 report Meet the Challenges  of Diabetes with Drug Innovation in Shanghai. The report shows the severe  diabetes current situation and prevention and control status of our country at  present, and introduces innovation drugs and the effect and meaning of diabetes  innovation management for improving patient’s life and reducing the burden.  


Diabetes is a  common chronic disease which may bring complications such  as eye disease, cardiovascular disease, pregnancy complications, diabetic foot  and mouth disease, kidney disease, nerve damage and so on. Nowadays the cure of  diabetes has become a focus of global attention, and the International Diabetes  Federation has made a short-term goal to make treatment and medicine available  to more and more type 2 diabetic patient.  


Diabetes treatment success rates are less than 50%, related fees  of diabetes increase rapidly  


China is the  world's number one diabetes country, with the largest number of patients in the  world, and its adult diabetes prevalence is higher than the world level.  According to the report of IDF, in 2015, there are 109.6 million diabetes  patients in our country and the number is predicted to rise to 150.7 million in  2040.  


Diabetes and  its complications bring great burden to patients and their family. In 2015, the  total fees of diseases related to diabetes in China is $51 billion, of which  84.6% of the cost is used for the treatment of complications. According to the  prediction of IDF, in 2040, the total fees of diseases related to diabetes in  China will reach $72 billion.  


“At  present, there is still a large gap between China and many other countries in  the field of diabetes treatment and control, only 36.5% of the patients was  diagnosed, of which only 32.2% of patients are undergoing diabetes medication.”  Prof. Shi Yongquan said, who is the director of endocrinology department, Shanghai  Changzheng Hospital, member of Chinese medical association’s diabetes branch  and deputy director of endocrine society of Shanghai medical association, “The treatment success rate for diabetes patients in China is only  49.2%. I hope that the government, NGO, enterprises and individuals should work  together to promote the development of innovation treatment as well as improve patients’  quality of life, and accelerate the achievement of the goal of China's  prevention and cure of diabetes.”  


178 kinds of diabetes drugs are under  research to assistant China to deal with the challenge of diabetes  


Type 2 diabetes is a kind of progressive  disease, many drugs have effect on the control of blood  sugar of patient initially, but as time goes on, they may lose effect.  Therefore, new drugs or replacement therapy are needed to control the blood  sugar. When this circumstance occurs, the access that patient gets other drugs  is of great importance. If diabetes is well controlled, the complications will  be less and the disease burden of patients and society will be also less. Now,  there are over 178 kinds of innovative diabetes drugs under research.  


Dr. Zhang  Kezhou, the vice president of Clinical & Medical & Regulatory Novo  Nordisk Greater China, said, “If diabetes patients can control the  disease, we will see fewer complications, which will lower the burden on  patients and their families. With an innovation-driven development strategy to  tackle this problem in China, we are seeing innovative  drugs that can effectively reduce in-hospital time and need for surgery, delay  the development of complications and improve patients’ quality of life.  


The  clinical research director of MSD China R&D Center, Tu Yingmei said, “In  order to deal with the challenge of diabetes, new diabetes drugs are fast  emerging, of which the research and development choose different point to  overcome diabetes. Some new drugs, in addition to the hypoglycemic, improved  the clinical outcomes, at the same time new diabetes drugs have gained more and  more data of the cardiovascular safety. The pathogenesis of diabetes is  complicated, so we need to work together, and strive to provide more safe and  effective diabetes drugs for patients.”  


“How to better  help diabetic patients control their conditions is the great challenge China is  facing. We need to, by in-depth understanding of patients’ diagnosis and  treatment paths, better understand their real needs and facing difficulties,  and maximize the treatment value that high quality innovative drugs and  solutions bring to patients.” The head of Diabetes Business Unit of Sanofi  China, Patrick Nowlin said, “In addition, we need to joint doctors, nurses and patients  to set up an integrated system of disease education and tracking; and establish  an overall solution that meets the practical needs of patients at each stage of  their treatment.”  


In January of  this year, the General Office of the State Council issued Chinese Long-term  Planning for Chronic Disease Prevention and Control (2017-2025), deploying  to strengthen our country's chronic disease prevention and control work. The  diabetes is key field of our country's long-term chronic disease prevention and  control work. Its main goal is that by 2025, for people aged 30 to 70, the  premature mortality caused by cardiovascular and cerebrovascular diseases,  cancer, chronic respiratory diseases and diabetes will reduce by 20% compared  with that in 2015. Gradually improve the residents' health and life expectancy  and effectively control the chronic disease burden. “Our goal is to innovate  more safe, effective and personalized treatment options for patient.” Eric  BOUTEILLER, Chairman of RDPAC, said: “We will work together with member  companies to help China achieve its goal of medium and long-term planning for  the fight against chronic diseases. At the same time, we also look forward to  working together so that more patients will benefit from innovative drugs as  soon as possible to better control the disease and enjoy life. “  



Related articles: